Description of CiNA Public Use Dataset

The NAACCR CiNA-Public Dataset is a new CiNA product that was first available for 1995-2013 data. The goal behind producing the CiNA Public Use Dataset is to provide faster, streamlined access to the CiNA data in order to increase CiNA data use and, ultimately, reduce the burden of cancer. The data will be available annually after publication of the CiNA monographs; generally in the summer.

The CiNA Public Use Dataset is a publically accessible, non-confidential data set with a limited number of variables, available in the SEER*Stat program. Access requires only a signed Data Use Agreement for access. There are other CiNA databases with more extensive variable set that require a proposal review, NAACCR IRB approval, and a “yes” consent by each participating registry. The CiNA Public Use the variable list is included at the end of this document. Many variables are recoded from the reported data for ease of use and standardization of analysis. There are no treatment variables available in the CiNA Public Use Dataset.

The dataset is comprised of two datasets. One allows a user to generate counts, rates and trends within the SEER*Stat system. This dataset includes age in the 19 age group categories. The second dataset allows the user to export the data as a case-listing to allow regression and other analysis in standard, statistical programs. This second dataset includes both age and site as categorical variables for US combined and Canada combined. A researcher will be able to access both data sets in the same SEER*Stat session but will only be able to export data from registries that have provided consent. SEER*Stat provides automatic cell suppression of <6 and scrambles the Patient IDs. At this time, the database allowing exporting is still under development.

Additional details about the CiNA Public Use Dataset are provided in this document. If you have questions about the NAACCR CiNA Public Dataset, please contact Recinda Sherman, Manager of Research and Data Use at rsherman@naaccr.org or 217-698-0800 x6.
Data Use Agreement for Researcher Access to the Public Use Data Set  
NAACCR CiNA-Public Dataset

These data are provided for the sole purpose of statistical reporting and analysis only. By using these data, you signify your agreement to comply with the following:

1. There will be no attempt to learn the identity of any person included in these data. If the identity of any person is discovered inadvertently, no disclosure or other use of the identity will be made, and I will notify NAACCR.
   Initials required: ______

2. The identification or contact of individuals is prohibited. I will not discuss in any manner, with any unauthorized person, information that would lead to identification of individuals described in the Data furnished by NAACCR.
   Initials required: ______

3. I will not attempt either to link—or permit others to link—the data with individually identified records in another database.
   Initials required: ______

4. I will not either release—or permit others to release—the data—in full or in part—to any person. I will not share my password for data access with any other individuals. All members of a research team who have access to the data must sign this data-use agreement.
   Initials required: ______

5. I will not use—or permit others to use—the data in any way other than for statistical reporting and analysis for public health research purposes. I must notify NAACCR if I discover that there has been any other use of the data.
   Initials required: ______

6. I agree that all data provided shall remain the sole property of NAACCR and may not be copied or reproduced in any form or manner without NAACCR’s prior written consent.
   Initials required: ______

7. I will cite the source of information in all publications. The appropriate citation is associated with the data file used.
   Initials required: ______

8. Uses of these data do not constitute an endorsement of the user’s opinion or conclusions by NAACCR, or any central registry in US or Canada, and none should be inferred.
   Initials required: ______

9. I understand that calculating rates or other statistics based on small numbers can raise statistical issues concerning accuracy and usefulness. I will use appropriate caution when presenting and interpreting results based on less than 20 cases.
   Initials required: ______

10. I agree that any and all reports or analyses of the Data shall contain only aggregate data and no report of the Data containing statistical cells with less than six (6) subjects shall be released.
    Initials required: ______

My signature indicates that I agree to comply with the above stated provisions.

First Name:       Last Name:  
Organization:      Email:  
Phone:       Signature:  

Questions or issues, please contact Recinda Sherman, rsherman@naaccr.org.
Citation

Please reference to the source of these data in any published document as indicated in SEER*Stat session.
For example:
NAACCR Incidence - CiNA Public File, 1995-2015 (which includes data from CDC’s National Program of Cancer Registries (NPCR), CCCR’s Provincial and Territorial Registries, and the NCI’s Surveillance, Epidemiology and End Results (SEER) Registries), North American Association of Central Cancer Registries.

Technical Documentation

The NAACCR CiNA-Public Dataset is distributed through SEER*Stat and contains individual records of cancer incidence among US and Canada residents diagnosed from 1995 – 2015. Confidentiality is maintained by aggregating data within individual records into categories, the number of which depends on whether analysis is run on individual states/registries or nation/North America.

The purpose of releasing cancer surveillance data is to inform public health decision making. Cancer rates are often needed for subgroups or for small populations in order to understand the burden of cancer in these groups or areas. But working with small numbers has two problems 1) working with small numbers, particularly linking with external data, has the potential for confidentiality breaches; and 2) small numbers raise statistical issues regarding the accuracy and, ultimately, the usefulness of the data.

- To preserve confidentiality of the data, data will be automatically suppressed for counts less than 6 based on potentially linkable variables (registry, sex, age, race, race/ethnicity, year of diagnosis and site). Please note, counts less than six may be released for other variables including behavior, stage or histology. However, these variables are not considered identifying variables.

- For issues of statistically stability, we advise caution in interpreting rates and other results based on fewer than 25 cases.

Software

SEER*Stat statistical software is a standard tool for analysis of cancer-related data. SEER*Stat is distributed with the CiNA Public Dataset. Additional information on SEER*Stat is available on the NCI, SEER site: http://seer.cancer.gov/seerstat/. Tutorials are available here: http://seer.cancer.gov/seerstat/tutorials/. Delay factors, survival statistics, and prevalence are not currently available for the CiNA Public Dataset.

Representation

To be included in the CiNA Public dataset, a central registry from the US or Canada must meet specific data quality standards. All Gold and Silver NAACCR-certified central registries are eligible for inclusion in the CiNA Public dataset. Each central registry must also consent to the use of their data in the CiNA Public dataset. A current list of certified
registries is available here: https://www.naaccr.org/certified-registries/. Registries may have not been certified in prior years, but if their data quality improves over time, their data is included in CiNA. However, not all states meet the data quality criteria for each year and will have zero counts for those years. Current CiNA Public Use dataset contains 46 states plus DC and PR for the US, and 12 Canadian provinces covering 93% of the US and 64% of the Canada population.

Data Collection

Cancer registry data is collected in an on-going, systematic, and standardized process. In Canada, the cancer registry collection program is overseen by the Canadian Council of Cancer Registries. In the US, there are two cancer registry collection programs—the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER Program) and the Center for Disease Control’s National Program of Cancer Registries (NPCR). Data for all three programs is collected in a coordinated process from hospitals and other medical facilities, including inpatient, outpatient, and standalone facilities. The data is collected or overseen by certified tumor registrars (CTRs) who are highly trained medical professionals to ensure complete and high quality data collection. The International Classification of Disease-Oncology (ICD-O) coding system is used to code topography (primary site) and morphology (histologic characteristics) of the collected cancers. Additional coding information is available in the NAACCR Data Standards & Data Dictionary (Volume II) available here: https://www.naaccr.org/data-standards-data-dictionary/.

Please note, the variables available in the CiNA Public Dataset are a subset of the full variable list collected. Many variables in the CiNA Public Dataset are aggregated and recoded for analysis.

Cancer Coding Changes Over Time

Several definitional changes occurred in some histology and behavior codes in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. The changes predominately affected leukemias, lymphomas, and cancer of the ovary. One category of change between ICD-O-2 and ICD-O-3 is the manner in which leukemias and lymphomas are classified and coded. Although conversion of histology codes from ICD-O-2 to ICD-O-3 for cases diagnosed prior to 2001 helps minimize these differences, some minor differences may still exist, particularly with respect to some relatively rare lymphocytic cancers that can be coded to either leukemia or lymphoma.

Starting with ICD-O-3, several myelodysplastic diseases and syndromes are considered malignant, and, therefore, are now reportable for cases diagnosed in 2001 and later and are included in these data. Leukemias that represent a disease progression from one of the myelodysplastic diseases or syndromes diagnosed in 2001 and forward are no longer reportable.

For pediatric cancers, differences in incidence rates may be due to changes between the second and third edition of the International Classification of Childhood Cancers
Two changes in the ICCC-3 classification are main contributors to this change.

1) Burkitt lymphoma and unspecified lymphoma, which were separated from non-Hodgkin lymphoma previously are combined with non-Hodgkin lymphoma; 2) Some lymphomas, which were grouped in the miscellaneous lymphoreticular neoplasms previously, are now included in the non-Hodgkin lymphoma category. Pilocytic astrocytoma is considered to have uncertain behavior in the published version of ICD-O-3, but is reportable as a malignant cancer in North America. Including the childhood astrocytomas in the category of malignant brain tumors may introduce differences between childhood brain cancer rates in North America compared to other areas of the world that may not include these tumors as malignant.

In addition, mesothelioma and Kaposi sarcoma cases are reported as separate categories. This change has little or no impact on most rates for specific cancers.
Variable List

Demographic  State/Province
Demographic  Recode: Country
Demographic  Sex
Demographic  Recode: Age
Demographic  Recode: Race
Demographic  Recode: Hispanic
Cancer ID  Recode: Central Seq #
Cancer ID  Dx date year only
Cancer ID  Recode: Behavior
Cancer ID  Recode: Primary Site plus with Meso & KS
Cancer ID  Recode: ICCC
Cancer ID  Recode: CBTRUS for brain
Cancer ID  Recode: Histology
Cancer ID  Recode: Summary Stage
Cancer ID  Laterality
Cancer ID  Grade
Cancer ID  Diagnostic confirmation
Cancer ID  Recode: Report Source

Derived  CBTRUS brain and CSN histologic groupings—Under development
Derived  MP using IARC rules & SEER
Derived  County-Level Urban/Rural Status Code
Derived  County-Level Poverty Code
Derived  SES Composite (SEER)—under development

Variable Codes:

State: Name of state/province (Will include only high quality registries following CiNA monograph standards)

Country: 2 codes (US, Canada)—Derived code

Sex: T (includes all categories), M, F, unk

Age: 5-year aggregates; 0-4, 5-9,...75-79, 80-84, 85+, no unknown age

Race: (US only)
National: W, B, API, AIAN (AIAN is based on CHDSA counties only; recoded into race variable), Unk; and W, B, O, unk. Race suppressed following CiNA monograph standards (<6 in numerator).

Race/ethnicity:
Hispanic All Races, Non-Hispanic White, Non-Hispanic Black, Non-Hispanic Other, Non-Hispanic Unknown Race, Unknown Hispanic (based on NHIA). Race/ethnicity suppressed following CiNA monograph standards (<6 in numerator).

**Central Seq #:** variable collapsed
One primary only, 1st of 2 or more primaries; 2nd of 2 or more primaries; 3rd of 3 or more primaries, 4th of 4 or more primaries; 5th of 5 or more primaries; 6th or more of 6 or more primaries

**Year of Diagnosis:** 1995-2013

**Behavior:**
Benign, Borderline, In situ, Malignant, Only Malignant in ICD-O-3, No longer Reportable in ICD-O-3, Only malignant 2010+
Primary Site (03): based on ICD-O-3 regardless of diagnosis date; suppression rules apply

All Sites
Oral Cavity and Pharynx
    Lip
    Tongue
    Salivary Gland
    Floor of Mouth
    Gum and Other Mouth
    Nasopharynx
    Tonsil
    Oropharynx
    Hypopharynx
    Other Oral Cavity and Pharynx
Digestive System
    Esophagus
    Stomach
    Small Intestine
    Colon and Rectum
    Colon excluding Rectum
    Cecum
    Appendix
    Ascending Colon
    Hepatic Flexure
    Transverse Colon
    Splenic Flexure
    Descending Colon
    Sigmoid Colon
    Large Intestine, NOS
    Rectum and Rectosigmoid Junction
    Rectosigmoid Junction
    Rectum
    Anus, Anal Canal and Anorectum
Liver and Intrahepatic Bile Duct
    Liver
    Intrahepatic Bile Duct
    Gallbladder
    Other Biliary
    Pancreas
    Retroperitoneum
    Peritoneum, Omentum and Mesentery
    Other Digestive Organs
Respiratory System
  Nose, Nasal Cavity and Middle Ear
  Larynx
  Lung and Bronchus
  Pleura
  Trachea, Mediastinum and Other
Respiratory Organs
  Bones and Joints
  Soft Tissue including Heart
Skin excluding Basal and Squamous
  Melanoma of the Skin
  Other Non-Epithelial Skin
Breast
Female Genital System
  Cervix Uteri
  Corpus and Uterus, NOS
    Corpus Uteri
    Uterus, NOS
  Ovary
  Vagina
  Vulva
  Other Female Genital Organs
Male Genital System
  Prostate
  Testis
  Penis
  Other Male Genital Organs
Urinary System
  Urinary Bladder
  Kidney and Renal Pelvis
  Ureter
  Other Urinary Organs
Eye and Orbit
Brain and Other Nervous System
  Brain
  Cranial Nerves Other Nervous System
Endocrine System
  Thyroid
  Other Endocrine including Thymus
Lymphoma
  Hodgkin Lymphoma
    Hodgkin - Nodal
    Hodgkin - Extranodal
Non-Hodgkin Lymphoma
  NHL - Nodal
  NHL - Extranodal
Myeloma
Leukemia
  Lymphocytic Leukemia
    Acute Lymphocytic Leukemia
    Chronic Lymphocytic Leukemia
    Other Lymphocytic Leukemia
Myeloid and Monocytic Leukemia
  Acute Myeloid Leukemia
  Acute Monocytic Leukemia
  Chronic Myeloid Leukemia
  Other Myeloid/Monocytic Leukemia
Other Leukemia
  Other Acute Leukemia
    Aleukemic, Subleukemic and NOS
Mesothelioma
Kaposi Sarcoma
Miscellaneous
Histology (03): based on ICD-O-3 regardless of diagnosis date

8000/0: Neoplasm, benign
8000/1: Neoplasm, uncertain whether benign or malignant
8000/2: Neoplasm, in situ
8000/3: Neoplasm, malignant
8001/0: Tumor cells, benign
8001/1: Tumor cells, uncertain whether benign or malignant
8001/3: Tumor cells, malignant
8002/3: Malignant tumor, small cell type
8003/1
8003/3: Malignant tumor, giant cell type
8004/0
8004/3: Malignant tumor, spindle cell type
8005/1
8005/3: Malignant tumor, clear cell type
8010/0: Epithelial tumor, benign
8010/1
8010/2: Carcinoma in situ, NOS
8010/3: Carcinoma, NOS
8011/2: Epithelioma, in situ
8011/3: Epithelioma, malignant
8012/2: Large cell carcinoma in situ
8012/3: Large cell carcinoma, NOS
8013/3: Large cell neuroendocrine carcinoma
8014/2
8014/3: Large cell carcinoma with rhabdoid phenotype
8015/3: Glassy cell carcinoma
8020/2
8020/3: Carcinoma, undifferentiated type, NOS
8021/3: Carcinoma, anaplastic type, NOS
8022/2: Pleomorphic carcinoma in situ
8022/3: Pleomorphic carcinoma
8030/2: Giant cell and spindle cell carcinoma in situ
8030/3: Giant cell and spindle cell carcinoma
8031/2: Giant cell carcinoma in situ
8031/3: Giant cell carcinoma
8032/2: Spindle cell carcinoma in situ
8032/3: Spindle cell carcinoma
8033/2: Pseudosarcomatous carcinoma, in situ
8033/3: Pseudosarcomatous carcinoma
8034/3: Polygonal cell carcinoma
8035/3: Carcinoma with osteoclast-like giant cells
8040/1: Tumorlet, NOS
8040/3: Tumorlet, malignant
8041/2: Small cell carcinoma in situ
8041/3: Small cell carcinoma, NOS
8042/2: Oat cell carcinoma in situ
8042/3: Oat cell carcinoma
8043/3: Small cell carcinoma, fusiform cell
8044/3: Small cell carcinoma, intermediate cell
8045/3: Combined small cell carcinoma
8046/2: Non-small cell carcinoma in situ
8046/3: Non-small cell carcinoma
8050/0
8050/2: Papillary carcinoma in situ
8050/3: Papillary carcinoma, NOS
8051/2: Verrucous papilloma in situ
8051/3: Verrucous carcinoma, NOS
8052/2: Papillary squamous cell carcinoma, non-invasive
8052/3: Papillary squamous cell carcinoma
8053/2
8053/3: Papillary squamous cell carcinoma, inverted
8060/3
8070/2: Squamous cell carcinoma in situ, NOS
8070/3: Squamous cell carcinoma, NOS
8071/2: Squamous cell carcinoma in situ, keratinizing, NOS
8071/3: Squamous cell carcinoma, keratinizing, NOS
8072/2: Squamous cell CIS, large cell, nonkeratinizing
8072/3: Squamous cell ca., large cell, nonkeratinizing
8073/2: Squamous cell CIS, small cell, nonkeratinizing
8073/3: Squamous cell ca., small cell, nonkeratinizing
8074/2: Squamous cell carcinoma in situ, spindle cell
8074/3: Squamous cell carcinoma, spindle cell
8075/2: Squamous cell carcinoma in situ, adenoid
8075/3: Squamous cell carcinoma, adenoid
8076/2: Squamous cell CIS with questionable stromal invasion
8076/3: Squamous cell carcinoma, micro-invasive
8077/2: Squamous intraepithelial neoplasia, grade III
8077/3: Squamous cell ca. & Grade III
8078/3: Squamous cell carcinoma with horn formation
8080/2: Queyrat erythroplasia
8080/3: Queyrat erythroplasia, malignant
8081/2: Bowen disease
8081/3: Bowen disease, malignant
8082/3: Lymphoepithelial carcinoma
8083/2: Basaloid squamous cell carcinoma in situ
8083/3: Basaloid squamous cell carcinoma
8084/3: Squamous cell carcinoma, clear cell type
8090/2: Basal cell carcinoma in situ
8090/3: Basal cell carcinoma, NOS
8091/2: Multicentric basal cell carcinoma in situ
8091/3: Multifocal superficial basal cell carcinoma
8092/3: Infiltrating basal cell carcinoma, NOS
8093/3: Basal cell carcinoma, fibroepithelial
8094/2: Basosquamous carcinoma in situ
8094/3: Basosquamous carcinoma
8095/3: Metatypical carcinoma
8097/2
8097/3: Basal cell carcinoma, nodular
8098/3: Adenoid basal cell carcinoma
8100/3: Trichoepithelioma, malignant
8101/3
8102/3: Trichilemmocarcinoma
8103/0
8103/3: Pilar tumor, malignant
8110/3: Pilomatrix carcinoma
8120/0
8120/2: Transitional cell carcinoma in situ
8120/3: Transitional cell carcinoma, NOS
8121/2: Transitional cell carcinoma in situ, inverted, NOS
8121/3: Schneiderian carcinoma
8122/2
8122/3: Transitional cell carcinoma, spindle cell
8123/2: Basaloid carcinoma in situ
8123/3: Basaloid carcinoma
8124/2: Cloacogenic carcinoma in situ
8124/3: Cloacogenic carcinoma
8130/2: Papillary transitional cell carcinoma, non-invasive
8130/3: Papillary transitional cell carcinoma
8131/2: Transitional cell carcinoma in situ, micropapillary
8131/3: Transitional cell carcinoma, micropapillary
8140/0: Adenoma, NOS
8140/1: Atypical adenoma
8140/2: Adenocarcinoma in situ
8140/3: Adenocarcinoma, NOS
8141/3: Scirrhous adenocarcinoma
8142/2
8142/3: Linitis plastica
8143/2: Superficial spreading adenocarcinoma in situ
8143/3: Superficial spreading adenocarcinoma
8144/2: Adenocarcinoma in situ, intestinal type
8144/3: Adenocarcinoma, intestinal type
8145/2: Carcinoma in situ, diffuse type
8145/3: Carcinoma, diffuse type
8146/0: Monomorphic adenoma
8146/3: Monomorphic adenocarcinoma
8147/2
8147/3: Basal cell adenocarcinoma
8148/2: Glandular intraepithelial neoplasia, grade III
8148/3: Glandular neoplasia, malignant, Grade III
8149/3
8150/3: Islet cell carcinoma
8151/3: Insulinoma, malignant
8152/3: Glucagonoma, malignant
8153/3: Gastrinoma, malignant
8154/3: Mixed islet cell and exocrine adenocarcinoma
8155/3: Vipoma
8156/3: Somatostatinoma, malignant
8160/2: Bile duct adenocarcinoma in situ
8160/3: Cholangiocarcinoma
8161/3: Bile duct cystadenocarcinoma
8162/2
8162/3: Klatskin tumor
8170/2: Hepatocellular carcinoma in situ
8170/3: Hepatocellular carcinoma, NOS
8171/3: Hepatocellular carcinoma, fibrolamellar
8172/0
8172/3: Hepatocellular carcinoma, scirrhous
8173/3: Hepatocellular carcinoma, spindle cell variant
8174/3: Hepatocellular carcinoma, clear cell type
8175/3: Hepatocellular carcinoma, pleomorphic type
8180/2
8180/3: Combined hepatocellular ca. & cholangiocarcinoma
8190/3: Trabecular adenocarcinoma
8200/2: Adenoid cystic carcinoma in situ
8200/3: Adenoid cystic carcinoma
8201/2: Cribriform carcinoma in situ
8201/3: Cribriform carcinoma
8202/0: Microcystic adenoma
8202/3
8210/2: Adenocarcinoma in situ in adenomatous polyp
8210/3: Adenocarcinoma in adenomatous polyp
8211/2: Tubular adenocarcinoma in situ
8211/3: Tubular adenocarcinoma
8212/2
8212/3
8213/2: Serrated adenocarcinoma, in situ
8213/3: Serrated adenocarcinoma
8214/3: Parietal cell carcinoma
8215/3: Adenocarcinoma of anal glands
8220/2: Adenocarcinoma in situ in adenomatous polyposis coli
8220/3: Adenocarcinoma in adenomatous polyposis coli
8221/2: Adenoca. in situ in mult. adenomatous polyposis coli
8221/3: Adenocarcinoma in mult. adenomatous polyposis coli
8230/2: Duct carcinoma in situ, solid type
8230/3: Solid carcinoma, NOS
8231/3: Carcinoma simplex
8240/2: Carcinoid tumor, in situ
8240/3: Carcinoid tumor, malignant
8241/2
8241/3: Enterochromaffin cell carcinoid
8242/0
8242/3: Enterochromaffin-like cell tumor, malignant
8243/2
8243/3: Goblet cell carcinoid
8244/3: Composite carcinoid
8245/2
8245/3: Adenocarcinoid tumor
8246/2: Neuroendocrine carcinoma in situ
8246/3: Neuroendocrine carcinoma
8247/2: Merkel cell carcinoma in situ
8247/3: Merkel cell carcinoma
8248/3: Apudoma
8249/3: Atypical carcinoid tumor
8250/2: Bronchiolo-alveolar adenocarcinoma in situ
8250/3: Bronchiolo-alveolar adenocarcinoma
8251/3: Alveolar adenocarcinoma
8252/2: Bronchiolo-alveolar carcinoma, non-mucinous, in situ
8252/3: Bronchiolo-alveolar carcinoma, non-mucinous
8253/2: Bronchiolo-alveolar carcinoma, mucinous, in situ
8253/3: Bronchiolo-alveolar carcinoma, mucinous
8254/3: Bronchiolo-alveolar ca., mucinous & non-mucinous
8255/2: Adenocarcinoma in situ with mixed subtypes
8255/3: Adenocarcinoma with mixed subtypes
8260/0: Papillary adenoma, NOS
8260/1
8260/2: Papillary adenocarcinoma in situ, NOS
8260/3: Papillary adenocarcinoma, NOS
8261/2: Adenocarcinoma in situ in villous adenoma
8261/3: Adenocarcinoma in villous adenoma
8262/2: Villous adenocarcinoma in situ
8262/3: Villous adenocarcinoma
8263/2: Adenocarcinoma in situ in tubulovillous adenoma
8263/3: Adenocarcinoma in tubulovillous adenoma
8264/3
8270/0: Chromophobe adenoma
8270/1: Chromophobe adenoma, borderline
8270/2
8270/3: Chromophobe carcinoma
8271/0: Prolactinoma
8271/1
8271/3: Prolactinoma, malignant
8272/0: Pituitary adenoma, NOS
8272/1: Pituitary, borderline malignancy
8272/3: Pituitary carcinoma, NOS
8280/0: Acidophil adenoma
8280/3: Acidophil carcinoma
8281/0: Mixed acidophil-basophil adenoma
8290/0: Oxyphilic adenoma
8290/2: Oxyphilic adenocarcinoma in situ
8290/3: Oxyphilic adenocarcinoma
8300/0: Basophil adenoma
8300/3: Basophil carcinoma
8310/0
8310/2: Clear cell adenocarcinoma in situ
8310/3: Clear cell adenocarcinoma, NOS
8312/2: Renal cell carcinoma in situ, NOS
8312/3: Renal cell carcinoma
8313/3: Clear cell adenocarcinofibroma
8314/3: Lipid-rich carcinoma
8315/2
8315/3: Glycogen-rich carcinoma
8316/2: Cyst-associated renal cell carcinoma in situ
8316/3: Cyst-associated renal cell carcinoma
8317/3: Renal cell carcinoma, chromophobe type
8318/3: Renal cell carcinoma, sarcomatoid
8319/2
8319/3: Collecting duct carcinoma
8320/2
8320/3: Granular cell carcinoma
8321/3
8322/3: Water-clear cell adenocarcinoma
8323/0: Mixed cell adenoma
8323/2: Mixed cell adenocarcinoma in situ
8323/3: Mixed cell adenocarcinoma
8325/3: Metanephric adenomacarcinoma
8330/2: Follicular adenocarcinoma in situ
8330/3: Follicular adenocarcinoma, NOS
8331/3: Follicular adenocarcinoma well differentiated
8332/3: Follicular adenocarcinoma trabecular
8333/3: Fetal adenocarcinoma
8334/0
8335/2: Macrofollicular carcinoma in situ
8335/3: Follicular carcinoma, minimally invasive
8336/3
8337/3: Insular carcinoma
8340/2: Papillary carcinoma in situ, follicular variant
8340/3: Papillary carcinoma, follicular variant
8341/0
8341/2: Papillary microcarcinoma in situ
8341/3: Papillary microcarcinoma
8342/3: Papillary carcinoma, oxyphilic cell
8343/2: Papillary carcinoma, encapsulated, in situ
8343/3: Papillary carcinoma, encapsulated
8344/2
8344/3: Papillary carcinoma, columnar cell
8345/3: Medullary carcinoma with amyloid stroma
8346/3: Mixed medullary-follicular carcinoma
8347/3: Mixed medullary-papillary carcinoma
8350/3: Nonencapsulated sclerosing carcinoma
8360/1: Multiple endocrine adenomas
8360/3
8361/3
8370/0
8370/2: Adrenal cortical carcinoma in situ
8370/3: Adrenal cortical carcinoma
8372/0
8380/2: Endometrioid adenocarcinoma in situ
8380/3: Endometrioid carcinoma
8381/2
8381/3: Endometrioid adenofibroma, malignant
8382/2: Endometrioid adenocarcinoma, secretory variant
8382/3: Endometrioid adenocarcinoma, secretory variant
8383/3: Endometrioid adenocarcinoma, ciliated cell variant
8384/2: Adenocarcinoma, endocervical type, in situ
8384/3: Adenocarcinoma, endocervical type
8390/2: Skin appendage carcinoma in situ
8390/3: Skin appendage carcinoma
8392/3: Syringofibroadenocarcinoma
8400/2: Sweat gland adenocarcinoma in situ
8400/3: Sweat gland adenocarcinoma
8401/2: Apocrine adenocarcinoma in situ
8401/3: Apocrine adenocarcinoma
8402/2: Nodular hidradenoma, in situ
8402/3: Nodular hidradenoma, malignant
8403/3: Malignant eccrine spiradenoma
8405/3: Papillary hidradenocarcinoma
8406/3: Papillary syringadenocarcinoma
8407/2
8407/3: Sclerosing sweat duct carcinoma
8408/3: Eccrine papillary adenocarcinoma
8409/2: Eccrine poroma, in situ
8409/3: Eccrine poroma, malignant
8410/2: Sebaceous adenocarcinoma in situ
8410/3: Sebaceous adenocarcinoma
8413/2: Eccrine adenocarcinoma, in situ
8413/3: Eccrine adenocarcinoma
8420/2
8420/3: Ceruminous adenocarcinoma
8430/2: Mucoepidermoid carcinoma in situ
8430/3: Mucoepidermoid carcinoma
8440/0
8440/2: Cystadenocarcinoma in situ
8440/3: Cystadenocarcinoma, NOS
8441/0
8441/2: Serous cystadenocarcinoma in situ, NOS
8441/3: Serous cystadenocarcinoma, NOS
8442/1: Serous cystadenoma, borderline malignancy
8442/2: Serous cystadenocarcinoma in situ
8442/3: Proliferating serous carcinoma
8443/3: Clear cell cystadenocarcinoma
8444/3: Clear cell cystic tumor, malignant
8450/2: Papillary cystadenocarcinoma in situ, NOS
8450/3: Papillary cystadenocarcinoma, NOS
8451/1: Papillary cystadenoma, borderline malignancy
8451/3
8452/0
8452/1
8452/2
8452/3: Solid pseudopapillary carcinoma
8453/2: Intraductal papillary-mucinous ca., non-invasive
8453/3: Intraductal papillary-mucinous carcinoma, invasive
8460/2: Papillary serous cystadenoca in situ, NOS
8460/3: Papillary serous cystadenocarcinoma
8461/2: Serous surface papillary carcinoma, in situ
8461/3: Serous surface papillary carcinoma
8462/1: Serous papillary cystic tumor, borderline malignancy
8462/2: Serous papillary cystadenocarcinoma in situ
8462/3: Papillary serous cystadenocarcinoma
8463/3: Serous surface papillary carcinoma
8470/2: Mucinous cystadenocarcinoma, non-invasive
8470/3: Mucinous cystadenocarcinoma, NOS
8471/2: Papillary mucinous cystadenoca situ, NOS
8471/3: Papillary mucinous cystadenocarcinoma
8472/1: Mucinous cystic tumor of borderline malignancy
8472/2: Mucinous cystic adenocarcinoma in situ
8472/3: Mucinous cystadenocarcinoma
8473/1: Papillary mucinous cystadenoma, borderline malig.
8473/2: Papillary mucinous cystadenocarcinoma, in situ
8473/3: Papillary pseudomucinous cystadenocarcinoma
8480/2: Mucinous adenocarcinoma in situ
8480/3: Mucinous adenocarcinoma
8481/2: Mucin-producing adenocarcinoma in situ
8481/3: Mucin-producing adenocarcinoma
8482/3: Mucinous adenocarcinoma, endocervical type
8490/0: Signet ring cell tumor, benign
8490/2: Signet ring cell carcinoma in situ
8490/3: Signet ring cell carcinoma
8500/2: Intraductal carcinoma, noninfiltrating, NOS
8500/3: Infiltrating duct carcinoma, NOS
8501/2: Comedocarcinoma, non-infiltrating
8501/3: Comedocarcinoma, NOS
8502/2: Secretory carcinoma in situ of breast
8502/3: Secretory carcinoma of breast
8503/2: Noninfiltrating intraductal papillary adenocarcinoma
8503/3: Intraductal papillary adenocarcinoma with invasion
8504/2: Noninfiltrating intracystic carcinoma
8504/3: Intracystic carcinoma, NOS
8507/2: Intraductal micropapillary carcinoma
8507/3: Ductal carcinoma, micropapillary
8508/2: Cystic hypersecretory carcinoma in situ
8508/3: Cystic hypersecretory carcinoma
8510/2: Medullary carcinoma in situ, NOS
8510/3: Medullary carcinoma, NOS
8512/2: Medullary carcinoma in situ with lymphoid stroma
8512/3: Medullary carcinoma with lymphoid stroma
8513/2
8513/3: Atypical medullary carcinoma
8514/2
8514/3: Duct carcinoma, desmoplastic type
8520/2: Lobular carcinoma in situ
8520/3: Lobular carcinoma, NOS
8521/2: Ductular carcinoma in situ
8521/3: Infiltrating ductular carcinoma
8522/2: Intraductal and lobular in situ carcinoma
8522/3: Infiltrating duct and lobular carcinoma
8523/2: Intraductal with other types of carcinoma in situ
8523/3: Infiltrating duct mixed with other types of ca.
8524/2: Lobular CIS with other CIS
8524/3: Infiltrating lobular mixed with other types of ca.
8525/2
8525/3: Polymorphous low grade adenocarcinoma
8530/3: Inflammatory carcinoma
8540/2: Paget disease, mammary, in situ
8540/3: Paget disease, mammary
8541/2: Paget disease in situ and intraductal carcinoma
8541/3: Paget disease and infiltrating duct carcinoma
8542/2: Paget disease in situ, extra mammary (except bone)
8542/3: Paget disease, extramammary
8543/2: Paget disease in situ and intraductal carcinoma
8543/3: Paget disease and intraductal carcinoma
8550/2: Acinar cell carcinoma in situ
8550/3: Acinar cell carcinoma
8551/3: Acinar cell cystadenocarcinoma
8560/2: Squamous cell CIS and glandular papilloma
8560/3: Adenosquamous carcinoma
8561/0
8561/3: Warthin tumor, malignant
8562/2: Epithelial-myoeppithelial carcinoma in situ
8562/3: Epithelial-myoeppithelial carcinoma
8570/2: Adenocarcinoma in situ with squamous metaplasia
8570/3: Adenocarcinoma with squamous metaplasia
8571/3: Adenocarcinoma w. cartilaginous & osseous metaplasia
8572/0: Adenoma with spindle cell metaplasia
8572/3: Adenocarcinoma with spindle cell metaplasia
8573/2: Adenocarcinoma in situ with apocrine metaplasia
8573/3: Adenocarcinoma with apocrine metaplasia
8574/2: Adenocarcinoma in situ with neuroendocrine differentiation
8574/3: Adenocarcinoma with neuroendocrine differentiation
8575/2
8575/3: Metaplastic carcinoma, NOS
8576/3: Hepatoid adenocarcinoma
8580/2: Thymoma, in situ, NOS
8580/3: Thymoma, malignant, NOS
8581/2
8581/3: Thymoma, type A, malignant
8582/2
8582/3: Thymoma, type AB, malignant
8583/3: Thymoma, type B1, malignant
8584/2
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>8584/3</td>
<td>Thymoma, type B2, malignant</td>
</tr>
<tr>
<td>8585/3</td>
<td>Thymoma, type B3, malignant</td>
</tr>
<tr>
<td>8586/3</td>
<td>Thymic carcinoma, NOS</td>
</tr>
<tr>
<td>8588/3</td>
<td>Spindle epithelial tumor with thymus-like element</td>
</tr>
<tr>
<td>8589/3</td>
<td>Carcinoma showing thymus-like element</td>
</tr>
<tr>
<td>8590/3</td>
<td>Sex cord-gonadal stromal tumor, malignant, NOS</td>
</tr>
<tr>
<td>8591/3</td>
<td></td>
</tr>
<tr>
<td>8592/3</td>
<td></td>
</tr>
<tr>
<td>8593/3</td>
<td>Malignant Stromal tumor, with sex cord elements</td>
</tr>
<tr>
<td>8600/3</td>
<td>Thecoma, malignant</td>
</tr>
<tr>
<td>8602/3</td>
<td>Sclerosing stromal tumor, malignant</td>
</tr>
<tr>
<td>8620/2</td>
<td></td>
</tr>
<tr>
<td>8620/3</td>
<td>Granulosa cell tumor, malignant</td>
</tr>
<tr>
<td>8621/3</td>
<td>Granulosa cell-theca cell tumor, malignant</td>
</tr>
<tr>
<td>8622/3</td>
<td>Juvenile granulosa cell tumor, malignant</td>
</tr>
<tr>
<td>8623/3</td>
<td>Sex cord tumor with annular tubules, malignant</td>
</tr>
<tr>
<td>8630/3</td>
<td>Androblastoma, malignant</td>
</tr>
<tr>
<td>8631/3</td>
<td>Sertoli-Leydig cell tumor, poorly differentiated</td>
</tr>
<tr>
<td>8632/3</td>
<td>Gynandroblastoma, malignant</td>
</tr>
<tr>
<td>8633/3</td>
<td></td>
</tr>
<tr>
<td>8634/3</td>
<td>Sertoli-Leydig, poor diff. w. heterologous elements</td>
</tr>
<tr>
<td>8640/2</td>
<td></td>
</tr>
<tr>
<td>8640/3</td>
<td>Sertoli cell carcinoma</td>
</tr>
<tr>
<td>8642/3</td>
<td></td>
</tr>
<tr>
<td>8650/2</td>
<td></td>
</tr>
<tr>
<td>8650/3</td>
<td>Leydig cell tumor, malignant</td>
</tr>
<tr>
<td>8670/2</td>
<td></td>
</tr>
<tr>
<td>8670/3</td>
<td>Steroid cell tumor, malignant</td>
</tr>
<tr>
<td>8680/0</td>
<td>Paraganglioma, benign</td>
</tr>
<tr>
<td>8680/1</td>
<td>Paraganglioma, NOS</td>
</tr>
<tr>
<td>8680/3</td>
<td>Paraganglioma, malignant</td>
</tr>
<tr>
<td>8682/1</td>
<td></td>
</tr>
<tr>
<td>8683/0</td>
<td></td>
</tr>
<tr>
<td>8683/1</td>
<td></td>
</tr>
<tr>
<td>8683/3</td>
<td>Gangliocytic paraganglioma, malignant</td>
</tr>
<tr>
<td>8690/0</td>
<td></td>
</tr>
<tr>
<td>8690/1</td>
<td>Glomus jugulare tumor, NOS</td>
</tr>
<tr>
<td>8690/3</td>
<td>Glomus jugulare tumor, malignant</td>
</tr>
<tr>
<td>8692/3</td>
<td>Carotid body tumor, malignant</td>
</tr>
<tr>
<td>8693/1</td>
<td>Extra-adrenal paraganglioma, NOS</td>
</tr>
<tr>
<td>8693/3</td>
<td>Extra-adrenal paraganglioma, malignant</td>
</tr>
</tbody>
</table>
8700/0
8700/3: Pheochromocytoma
8710/2
8710/3: Glomangiosarcoma
8711/0: Glomus tumor, NOS
8711/3: Glomus tumor, malignant
8712/0
8713/0
8713/3
8720/0: Pigmented nevus, NOS
8720/2: Melanoma in situ
8720/3: Malignant melanoma, NOS
8721/2: Nodular melanoma, in situ
8721/3: Nodular melanoma
8722/2: Balloon cell melanoma, in situ
8722/3: Balloon cell melanoma
8723/2: Melanoma in situ, regressing
8723/3: Malignant melanoma, regressing
8726/0: Magnocellular nevus
8726/1
8726/3: Malignant melanoma in magnocellular nevus
8727/3: Dysplastic nevus, malignant
8728/0
8728/1: Meningeal melanocytoma
8728/2
8728/3: Meningeal melanomatosis
8730/2: Amelanotic melanoma, in situ
8730/3: Amelanotic melanoma
8740/2: Melanoma in situ in junctional nevus
8740/3: Malignant melanoma in junctional nevus
8741/2: Precancerous melanosis, NOS
8741/3: Malignant melanoma in precancerous melanosis
8742/2: Lentigo maligna
8742/3: Lentigo maligna melanoma
8743/2: Superficial spreading melanoma, in situ
8743/3: Superficial spreading melanoma
8744/2: Acral lentiginous melanoma, in situ
8744/3: Acral lentiginous melanoma, malignant
8745/2: Desmoplastic melanoma, in situ
8745/3: Desmoplastic melanoma, malignant
8746/2: Mucosal lentiginous melanoma in situ
8746/3: Mucosal lentiginous melanoma
8750/2
8750/3
8760/2: Melanoma in situ in compound nevus
8760/3: Malignant melanoma in compound nevus
8761/2: Melanoma in situ in giant pigmented nevus
8761/3: Malignant melanoma in giant pigmented nevus
8770/2: Epithelioid and spindle cell melanoma in situ
8770/3: Mixed epithelioid and spindle cell melanoma
8771/2: Epithelioid cell melanoma in situ
8771/3: Epithelioid cell melanoma
8772/0
8772/2: Spindle cell melanoma in situ, NOS
8772/3: Spindle cell melanoma, NOS
8773/3: Spindle cell melanoma, type A
8774/2
8774/3: Spindle cell melanoma, type B
8780/2
8780/3: Blue nevus, malignant
8790/3: Cellular blue nevus, malignant
8800/0: Soft tissue tumor, benign
8800/3: Sarcoma, NOS
8801/3: Spindle cell sarcoma
8802/3: Giant cell sarcoma
8803/3: Small cell sarcoma
8804/3: Epithelioid sarcoma
8805/3: Undifferentiated sarcoma
8806/3: Desmoplastic small round cell tumor
8810/0: Fibroma, NOS
8810/3: Fibrosarcoma, NOS
8811/1
8811/3: Fibromyxosarcoma
8812/3: Periosteal fibrosarcoma
8813/3: Fascial fibrosarcoma
8814/3: Infantile fibrosarcoma
8815/0: Solitary fibrous tumor
8815/1
8815/3: Solitary fibrous tumor, malignant
8820/0: Elastofibroma
8821/1: Aggressive fibromatosis
8821/3: Aggressive fibromatosis, malignant
8822/2
8822/3: Abdominal fibromatosis, malignant
8823/3: Desmoplastic fibrosarcoma
8824/0
8824/1
8824/3: Myofibroma, malignant
8825/0: Myofibroblastoma
8825/1: Myofibroblastic tumor, NOS
8825/2
8825/3: Myofibroblastoma, malignant
8826/3: Angiomyofibroblastoma, malignant
8830/0: Fibrous histiocytoma, benign
8830/1
8830/3: Fibrous histiocytoma, malignant
8831/0
8831/3: Histiocytoma, NOS, malignant
8832/3: Dermatofibrosarcoma, NOS
8833/3: Pigmented dermatofibrosarcoma protuberans
8835/1
8835/3: Malignant plexiform fibrohistiocytic tumor
8836/1
8836/3: Malignant angiomatoid fibrous histiocytoma
8840/0
8840/3: Myxosarcoma
8841/1
8841/3: Angiomyxoma, malignant
8842/0
8842/3: Ossifying fibromyxoid tumor, malignant
8850/0: Lipoma, NOS
8850/1: Atypical lipoma
8850/3: Liposarcoma, NOS
8851/0: Fibrolipoma
8851/3: Liposarcoma, well differentiated
8852/3: Myxoid liposarcoma
8853/3: Round cell liposarcoma
8854/0
8854/3: Pleomorphic liposarcoma
8855/3: Mixed type liposarcoma
8856/0: Intramuscular lipoma
8856/3
8857/0
8857/3: Fibroblastic liposarcoma
8858/3: Dedifferentiated liposarcoma
8860/3: Angiomyoliposarcoma
8861/0: Angiolipoma, NOS
8861/3
8870/0
8870/3
8880/3
8881/1
8890/0: Leiomyoma, NOS
8890/3: Leiomyosarcoma, NOS
8891/3: Epithelioid leiomyosarcoma
8892/3
8893/3: Bizarre leiomyosarcoma
8894/0: Angiomyoma
8894/3: Angiomyosarcoma
8895/3: Myosarcoma
8896/3: Myxoid leiomyosarcoma
8897/1: Smooth muscle tumor, NOS
8897/3: Malignant tumor of smooth muscle
8900/0: Rhabdomyoma, NOS
8900/3: Rhabdomyosarcoma, NOS
8901/3: Pleomorphic rhabdomyosarcoma, adult type
8902/3: Mixed type rhabdomyosarcoma
8904/0
8910/3: Embryonal rhabdomyosarcoma
8912/3: Spindle cell rhabdomyosarcoma
8920/3: Alveolar rhabdomyosarcoma
8921/3: Rhabdomyosarcoma with ganglionic differentiation
8930/3: Endometrial stromal sarcoma
8931/3: Endometrial stromal sarcoma, low grade
8932/3
8933/2
8933/3: Adenosarcoma
8934/3: Carcinofibroma
8935/0: Stromal tumor, benign
8935/3: Stromal sarcoma, NOS
8936/2: Gastrointestinal stromal tumor, NOS, in situ
8936/3: Gastrointestinal stromal sarcoma
8940/0: Pleomorphic adenoma
8940/2
8940/3: Mixed tumor, malignant, NOS
8941/2: Carcinoma in situ in pleomorphic adenoma
8941/3: Carcinoma in pleomorphic adenoma
8950/3: Mullerian mixed tumor
8951/3: Mesodermal mixed tumor
8959/3: Malignant cystic nephroma
8960/1
8960/3: Nephroblastoma, NOS
8963/3: Malignant rhabdoid tumor
8964/3: Clear cell sarcoma of kidney
8970/3: Hepatoblastoma
8971/3: Pancreatoblastoma
8972/3: Pulmonary blastoma
8973/3: Pleuropulmonary blastoma
8974/3
8980/3: Carcinosarcoma, NOS
8981/3: Carcinosarcoma, embryonal type
8982/0
8982/2
8982/3: Malignant myoepithelioma
8983/2: Adenomyoepithelioma, in situ
8983/3: Adenomyoepithelioma, malignant
8990/0: Mesenchymoma, benign
8990/1: Mesenchymoma, NOS
8990/3: Mesenchymoma, malignant
8991/3: Embryonal sarcoma
9000/0: Brenner tumor, NOS
9000/3: Brenner tumor, malignant
9013/3: Adenofibroma, malignant
9014/2: Serous adenocarcinofibroma, in situ
9014/3: Serous adenocarcinofibroma
9015/3: Mucinous adenocarcinofibroma
9020/1: Phyllodes tumor, borderline
9020/2
9020/3: Phyllodes tumor, malignant
9040/0
9040/3: Synovial sarcoma, NOS
9041/3: Synovial sarcoma, spindle cell
9042/3: Synovial sarcoma, epithelioid cell
9043/3: Synovial sarcoma, biphasic
9044/3: Clear cell sarcoma, NOS (except of kidney M-8964/3)
9050/3: Mesothelioma, malignant
9051/0
9051/3: Fibrous mesothelioma, malignant
9052/3: Epithelioid mesothelioma, malignant
9053/3: Mesothelioma, biphasic, malignant
9055/3: Multicystic mesothelioma, malignant
9060/3: Dysgerminoma
9061/2: Seminoma, in situ
9061/3: Seminoma, NOS
9062/3: Seminoma, anaplastic
9063/2: Spermatocytic seminoma, in situ
9063/3: Spermatocytic seminoma
9064/0
9064/1
9064/2: Intratubular malignant germ cells
9064/3: Germinoma
9065/0
9065/2
9065/3: Germ cell tumor, nonseminomatous
9070/2: Embryonal carcinoma, NOS, in situ
9070/3: Embryonal carcinoma, NOS
9071/2
9071/3: Yolk sac tumor
9072/3: Polyembryoma
9073/3: Gonadoblastoma, malignant
9080/0: Teratoma, benign
9080/1: Teratoma, NOS
9080/2: Teratoma, in situ
9080/3: Teratoma, malignant, NOS
9081/3: Teratocarcinoma
9082/3: Malignant teratoma, undifferentiated
9083/3: Malignant teratoma, intermediate
9084/0: Dermoid cyst, NOS
9084/1
9084/3: Teratoma with malignant transformation
9085/2: Mixed germ cell tumor, in situ
9085/3: Mixed germ cell tumor
9090/3: Struma ovari, malignant
9091/3: Strumal carcinoid, malignant
9100/2: Choriocarcinoma in situ, NOS
9100/3: Choriocarcinoma
9101/2: Choriocarcinoma combined w. other germ cell elements, in situ
9101/3: Choriocarcinoma combined w. other germ cell elements
9102/2
9102/3: Malignant teratoma, trophoblastic
9103/3: Partial hydatidiform mole, malignant
9104/3: Malignant placental site trophoblastic tumor
9105/3: Trophoblastic tumor, epithelioid
9110/2
9110/3: Mesonephroma, malignant
9120/0: Hemangioma, NOS
9120/1: Hemangioma, NOS, borderline
9120/3: Hemangiosarcoma
9121/0: Cavernous hemangioma
9121/1: Cavernous hemangioma, borderline
9121/3
9122/0: Venous hemangioma
9122/1
9123/0: Racemose hemangioma
9124/3: Kupffer cell sarcoma
9125/0: Epithelioid hemangioma
9125/3: Epithelioid hemangiosarcoma
9130/0: Hemangioendothelioma, benign
9130/1: Hemangioendothelioma, NOS
9130/3: Hemangioendothelioma, malignant
9131/0: Capillary hemangioma
9131/3
9133/1: Epithelioid hemangioendothelioma, NOS
9133/3: Epithelioid hemangioendothelioma, malignant
9135/1
9136/1: Spindle cell hemangioendothelioma
9136/3
9140/3: Kaposi sarcoma
9150/0: Hemangiopericytoma, benign
9150/1: Hemangiopericytoma, NOS
9150/3: Hemangiopericytoma, malignant
9160/0: Angiofibroma, NOS
9160/3: Angiofibrosarcoma
9161/0: Acquired tufted hemangioma
9161/1: Hemangioblastoma
9161/3: Hemangioblastoma, malignant
9170/0: Lymphangioma, NOS
9170/3: Lymphangiosarcoma
9171/3
9172/0
9173/0: Cystic lymphangioma
9173/3
9174/3
9175/3
9180/0: Osteoma, NOS
9180/3: Osteosarcoma, NOS
9181/3: Chondroblastic osteosarcoma
9182/3: Fibroblastic osteosarcoma
9183/3: Telangiectatic osteosarcoma
9184/3: Osteosarcoma in Paget disease
9185/3: Small cell osteosarcoma
9186/3: Central osteosarcoma
9187/3: Instrosseous well differentiated osteosarcoma
9191/0
9192/3: Parosteal osteosarcoma
9193/3: Periosteal osteosarcoma
9194/3: High grade surface osteosarcoma
9195/3
9200/0
9200/1
9200/3: Malignant, osteosarcoma
9210/0
9210/1
9220/0: Chondroma, NOS
9220/1
9220/3: Chondrosarcoma, NOS
9221/3: Juxtacortical chondrosarcoma
9230/3: Chondroblastoma, malignant
9231/3: Myxoid chondrosarcoma
9240/3: Mesenchymal chondrosarcoma
9241/0
9241/3
9242/3: Clear cell chondrosarcoma
9243/3: Dedifferentiated chondrosarcoma
9250/1: Giant cell tumor of bone, NOS
9250/3: Giant cell tumor of bone, malignant
9251/1
9251/3: Malignant giant cell tumor of soft parts
9252/0: Tenosynovial giant cell tumor
9252/3: Malignant tenosynovial giant cell tumor
9260/3: Ewing sarcoma
9261/3: Adamantinoma of long bones
9262/0
9270/3: Odontogenic tumor, malignant
9282/3: Complex odontosarcoma
9290/3: Ameloblastic odontosarcoma
9300/0
9302/3
9310/3: Ameloblastoma, malignant
9312/3: Squamous odontogenic tumor, malignant
9321/3: Central odontogenic fibrosarcoma
9330/3: Ameloblastic fibrosarcoma
9340/3
9341/3
9342/3: Odontogenic carcinosarcoma
9350/0: Craniopharyngioma, benign
9350/1: Craniopharyngioma
9350/3: Craniopharyngioma, malignant
9351/0: Craniopharyngioma, adamantinomatous, benign
9351/1: Adamantinomatous craniopharyngioma
9351/3: Malignant craniopharyngioma, adamantinomatous
9352/0: Papillary craniopharyngioma, benign
9352/1: Papillary craniopharyngioma
9360/0: Pinealoma, benign
9360/1: Pinealoma, NOS
9361/0: Pineocytoma, benign
9361/1: Pineocytoma
9361/3: Pineocytoma, malignant
9362/0
9362/1
9362/3: Pineoblastoma
9363/3: Melanotic neuroectodermal tumor, malignant
9364/3: Peripheral neuroectodermal tumor
9365/3: Askin tumor
9370/0
9370/1: Chordoma, borderline malignancy
9370/3: Chordoma, NOS
9371/3: Chondroid chordoma
9372/3: Dedifferentiated chordoma
9373/3
9380/0: Glioma, benign
9380/1: Glioma, borderline
9380/3: Glioma, malignant
9381/0: Gliomatosis cerebri, benign
9381/1
9381/3: Gliomatosis cerebri
9382/0: Mixed glioma, benign
9382/3: Mixed glioma
9383/0: Subependymoma, benign
9383/1: Subependymoma
9383/3: Subependymoma, malignant
9384/0: Subependymal giant cell astrocytoma, benign
9384/1: Subependymal giant cell astrocytoma
9384/3: Subependymal giant cell astrocytoma, malignant
9390/0: Choroid plexus papilloma, NOS
9390/1: Atypical choroid plexus papilloma
9390/3: Choroid plexus papilloma, malignant
9391/0: Ependymoma, benign
9391/1: Ependymoma, borderline
9391/3: Ependymoma, NOS
9392/3: Ependymoma, anaplastic
9393/0: Papillary ependymoma, benign
9393/1
9393/3: Papillary ependymoma, NOS
9394/0: Myxopapillary ependymoma, benign
9394/1: Myxopapillary ependymoma
9394/3: Myxopapillary ependymoma, malignant
9400/0: Astrocytoma, benign
9400/1: Astrocytoma, borderline malignancy
9400/3: Astrocytoma, NOS
9401/0: Astrocytoma, anaplastic, benign
9401/3: Astrocytoma, anaplastic
9410/3: Protoplasmic astrocytoma
9411/0: Gemistocytic astrocytoma, benign
9411/3: Gemistocytic astrocytoma
9412/0: Desmoplastic infantile astrocytoma, benign
9412/1: Desmoplastic infantile astrocytoma
9412/3
9413/0: Dysembryoplastic neuroepithelial tumor
9413/1: Dysembryoplastic neuroepithelial tumor, borderline
9413/3: Dysembryoplastic neuroepithelial tumor, malignant
9420/0
9420/3: Fibrillary astrocytoma
9421/3: Pilocytic astrocytoma, malignant
9423/3: Polar spongioblastoma
9424/0
9424/3: Pleomorphic xanthoastrocytoma
9430/0
9430/3: Astroblastoma
9440/0: Glioblastoma, benign
9440/1: Glioblastoma, NOS, borderline
9440/3: Glioblastoma, NOS
9441/3: Giant cell glioblastoma
9442/1: Gliofibroma
9442/3: Gliosarcoma
9444/0
9444/1: Chordoid glioma
9444/3
9450/0: Oligodendroglioma, NOS, benign
9450/1: Oligodendroglioma, NOS, borderline
9450/3: Oligodendroglioma, NOS
9451/0
9451/1
9451/3: Oligodendroglioma, anaplastic
9460/0
9460/3: Oligodendroblastoma
9470/0
9470/3: Medulloblastoma, NOS
9471/3: Desmoplastic medulloblastoma
9472/3: Medulomyoblastoma
9473/0
9473/3: Primitive neuroectodermal tumor
9474/3: Large cell medulloblastoma
9480/3: Cerebellar sarcoma, NOS
9490/0: Ganglieneuroma
9490/1: Ganglieneuroma, borderline
9490/3: Ganglioneuroblastoma
9492/0: Gangliocytoma
9492/1
9493/0: Dysplastic gangliocytoma of cerebellum
9500/0: Neuroblastoma, NOS, benign
9500/2: Neuroblastoma, in situ, NOS
9500/3: Neuroblastoma, NOS
9501/3: Medullopithelioma, NOS
9502/3: Teratoid medulloepithelioma
9503/0
9503/3: Neuroepithelioma, NOS
9504/3
9505/0: Ganglioglioma, benign
9505/1: Ganglioglioma, NOS
9505/3: Ganglioglioma, anaplastic
9506/0: Central neurocytoma, benign
9506/1: Central neurocytoma
9506/3: Neurocytoma, malignant
9508/3: Atypical teratoid/rhabdoid tumor
9510/3: Retinoblastoma, NOS
9511/3: Retinoblastoma, differentiated
9512/3: Retinoblastoma, undifferentiated
9513/3: Retinoblastoma, diffuse
9520/0
9520/3: Olfactory neurogenic tumor
9521/3: Olfactory neurcytoma
9522/3: Olfactory neuroblastoma
9523/3: Olfactory neuroepithelioma
9530/0: Meningioma, NOS
9530/1: Meningiomatosis, NOS
9530/3: Meningioma, malignant
9531/0: Meningothelial meningioma
9531/1: Meningiothelial meningioma, borderline
9531/3: Meningiothelial meningioma, malignant
9532/0: Fibrous meningioma
9532/1
9532/3: Fibrous meningioma, malignant
9533/0: Psammomatous meningioma
9533/1
9533/3: Psammomatous meningioma, malignant
9534/0: Angiomatous meningioma
9534/1
9534/3: Angiomatous meningioma, malignant
9535/0: Hemangioblastic meningioma
9535/3: Hemangioblastic meningioma, malignant
9537/0: Transitional meningioma
9537/1
9537/3: Transitional meningioma, malignant
9538/0: Clear cell meningioma, benign
9538/1: Clear cell meningioma
9538/3: Papillary meningioma
9539/0: Atypical meningioma, benign
9539/1: Atypical meningioma, NOS
9539/3: Meningeal sarcomatosis
9540/0: Neurofibroma, NOS
9540/1: Neurofibromatosis, NOS
9540/3: Malignant peripheral nerve sheath tumor
9541/0: Melanotic neurofibroma
9550/0: Plexiform neurofibroma
9550/3: Plexiform neurofibrosarcoma
9560/0: Neurilemoma, NOS
9560/1: Neurinomatosis
9560/3: Neurilemmoma, malignant
9561/3: MPNST with rhabdomyoblastic differentiation
9562/0: Neurothekeoma
9562/3: Neurothekeoma, malignant
9570/0: Neuroma, NOS
9570/3
9571/0: Perineurioma, NOS
9571/1: Perineurioma, borderline malignancy
9571/3: Perineurioma, malignant
9571/3: Perineurioma, malignant
9572/0: Granular cell tumor, NOS
9573/0: Granular cell tumor, malignant
9573/3: Alveolar soft part sarcoma
9573/3: Alveolar soft part sarcoma
9580/0: Granular cell tumor of the sellar region
9580/0
9580/3: Granular cell tumor, malignant
9581/3: Alveolar soft part sarcoma
9582/0: Granular cell tumor of the sellar region
9590/0
9590/3: Malignant lymphoma, NOS
9591/3: Malignant lymphoma, non-Hodgkin, NOS
9596/3: B-cell lymphoma, between diffuse large B and HL (composite HL and NHL)
9597/3: Primary cutaneous follicle centre lymphoma
9650/3: Classical Hodgkin lymphoma
9651/3: Lymphocyte-rich classical Hodgkin lymphoma
9652/3: Mixed cellularity classical Hodgkin lymphoma
9653/3: Lymphocyte-depleted classical Hodgkin lymphoma
9654/3: Hodgkin lymphoma, LD, diffuse fibrosis (OBS 2010+) see 9651/3
9655/3: Hodgkin lymphoma, lymphocytic depleted, reticular
9659/3: Nodular lymphocyte predominant Hodgkin lymphoma
9661/3: Hodgkin granuloma (OBS 2010+) see 9651/3
9662/3: Hodgkin sarcoma (OBS 2010+) see 9651/3
9663/3: Nodular sclerosis classical Hodgkin lymphoma
9664/3: Hodgkin lymphoma, nodular sclerosis, cellular phase (OBS) see 9663/3
9665/3: Hodgkin lymphoma, nodular sclerosis, grade 1 (OBS 2010+) see 9663/3
9667/3: Hodgkin lymphoma, nodular sclerosis, grade 2 (OBS 2010+) see 9663/3
9670/3: Malignant lymphoma, small B lymphocytes, NOS (OBS 2010+) see 9823/3
9671/3: Lymphoplasmacytic lymphoma (NHL)
9673/3: Mantle cell lymphoma
9675/3: Malig lymphoma, mixed small & large cell, diffuse (OBS 2010+) see 9690/3
9678/3: Primary effusion lymphoma
9679/3: Primary mediastinal (thymic) large B-cell lymphoma
9680/3: Diffuse large B-cell (NHL) lymphoma (DLBCL)
9684/3: Malig. lymphoma, large B, diffuse, immunoblastic (OBS 2010+) See 9680/3
9687/3: Burkitt lymphoma
9688/3: T-cell histiocye-rich large B-cell lymphoma
9689/3: Splenic marginal zone (B-cell) lymphoma
9690/3: Follicular lymphoma, NOS
9691/3: Follicular lymphoma, grade 2
9695/3: Follicular lymphoma, grade 1
9698/3: Follicular lymphoma, grade 3
9699/3: Extranodal marginal zone lymphoma of mucosal-assoc. lymphoid tissue-MALT
9700/3: Mycosis fungoides
9701/3: Sezary syndrome
9702/3: Peripheral (mature) T-cell lymphoma, NOS
9705/3: Angioimmunoblastic T-cell lymphoma
9708/3: Subcutaneous panniculitis-like T-cell lymphoma
9709/3: Primary cutaneous T-cell lymphoma
9712/3: Intravascular large B-cell lymphoma
9714/3: Anaplastic large cell (T-cell and Null cell) lymphoma, ALK-positive
9716/3: Hepatosplenic (gamma-delta) T-cell lymphoma
9717/3: Enteropathy-associated T-cell (intestinal) lymphoma
9718/3: Primary cutaneous CD30-pos. T-cell (lymphoma) lymphoproliferative disor.
9719/3: Extranodal NK--/T-cell lymphoma, (nasal and ) nasal type
9724/3: Systemic EBV pos T-cell lymphoprolif dis of child
9726/3: Primary cutaneous gamma-delta T-cell lymphoma
9727/3: Blastic plasmacytoid dendritic cell neoplasm (prec b-cell leuk/lymph)
9728/3: Precursor B-lymphoblastic lymphoma (OBS 2010+) See 9811/3
9729/3: Precursor T--cell lymphoblastic lymphoma, NOS (OBS 2010+) See 9837/3
9731/3: Solitary plasmacytoma of bone/plasmacytoma, NOS
9732/3: Plasma cell (multiple) myeloma
9733/3: Plasma cell leukemia (OBS 2010+) See 9732/3
9734/3: Extraosseous (extramedullary) plasmacytoma
9735/3: Plasmablastic lymphoma
9737/3: ALK positive large B-cell lymphoma
9738/3: Large B-cell lymph HHV8 multicentric Castleman disease
9740/3: Mast cell sarcoma
9741/3: Malignant mastocytosis
9742/3: Mast cell leukemia
9750/1
9750/3: Malignant histiocytosis (OBS 2010+) see 9751/3
9751/0
9751/1: Langerhans cell histiocytosis, NOS
9751/3: Langerhans cell histiocytosis (malignant) (NOS)
9752/0
9752/1: Langerhans cell histiocytosis, unifocal (OBS 2010+) see 9751/3
9752/3
9753/1
9753/3: Langerhans cell histiocytosis, multifocal, malig (OBS 2010+) see 9751/3
9754/1: Langerhans cell histiocytosis, disseminated, borderline
9754/3: Langerhans cell histiocytosis, disseminated (OBS 2010+) see 9751/3
9755/3: Histiocytic sarcoma
9756/3: Langerhans cell sarcoma
9757/3: Interdigitating dendritic cell sarcoma
9758/3: Follicular dendritic cell sarcoma
9760/3: Immunoproliferative disease, NOS (OBS 2010+) see 9761/3 or 9762/3
9761/3: Waldenstrom macroglobulinemia
9762/3: Heavy chain disease
9764/3: Immunoproliferative small intestinal disease (OBS 2010+) see code 9762
9765/3: Monoclonal gammopathy, malignant
9766/1: Angiocentric immunoproliferative lesion
9766/3: Angiocentric immunoproliferative lesion, malignant
9768/3
9769/3: Immunoglobulin deposition disease (malignant)
9800/3: Leukemia, NOS
9801/3: Acute (undifferentiated) leukemia
9805/3: Acute biphenotypic leukemia (OBS 2010+) see codes 9806-9809
9806/3: Mixed pheno acute leuk w/t(9;22)(q34;q11.2);BCR-ABL1
9807/3: Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged
9808/3: Mixed phenotype acute leukemia, B/myeloid, NOS
9809/3: Mixed phenotype acute leukemia, T/myeloid, NOS
9811/3: B lymphoblastic leuk/lymph, NOS
9812/3: B lymphoblastic leuk/lymph w/t(9;22)(q34;q11.2); BCR-ABL1
9813/3: B lymphoblastic leuk/lymph w/t(v;11q23); MLL rearranged
9814/3: B lymphoblastic leuk/lymph w/t(12;21)(p13;q22); TEL-AML1
9815/3: B lymphoblastic leuk/lymph w/hyperdiploidy
9816/3: B lymphoblastic leuk/lymph w/hypodiploidy (hypodip ALL)
9817/3: B lymphoblastic leuk/lymph w/t(5;14)(q31;q32); IL3-IGH
9818/3: B lymphoblastic leuk/lymph w/t(1;19)(q23;p13.3); E2A PBX1
9820/3: Lymphoid leukemia, NOS
9823/3: Chronic lymphocytic leukemia/small lymphocytic lymphoma (B-cell)
9826/3: Burkitt cell leukemia
9827/3: Adult T-cell leukemia/lymphoma (HTLV-1 pos.)
9831/3: T-cell large granular lymphocytic leukemia
9832/3: Prolymphocytic leukemia, NOS
9833/3: B-cell prolymphocytic leukemia
9834/3: T-cell prolymphocytic leukemia
9835/3: Precursor cell lymphoblastic leukemia, NOS (OBS 2010+) see 9811/3
9836/3: Precursor B-cell lymphoblastic leukemia (OBS 2010+) see code 9811/3
9837/3: Adult T-cell leukemia/lymphoma
9840/3: Acute erythroid leukemia (M6 type)
9860/3: Myeloid leukemia, NOS
9861/3: Acute myeloid leukemia
9863/3: Chronic myeloid leukemia, NOS
9865/3: Acute myeloid leukemia w/t(6;9)(p23;q34) DEK-NUP214
9866/3: Acute promyelocytic leukemia (AML with t(15;17)(q22;q12)) PML/RARA
9867/3: Acute myelomonocytic leukemia
9869/3: Acute myeloid leuk. inv(3)(q21;q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
9870/3: Acute basophilic leukemia
9871/3: AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22), CBFB-MYH11
9872/3: Acute myeloid leukemia with minimal differentiation
9873/3: Acute myeloid leukemia without maturation
9874/3: Acute myeloid leukemia with maturation
9875/3: Chronic myelogenous leukemia, BCR/ABL positive
9876/3: Atypical chronic myeloid leukemia, BCR/ABL negative
9891/3: Acute monoblastic and monocytic leukemia
9895/3: AML with myelodysplasia-related changes ( multilineage dysplasia)
9896/3: Acute myeloid leukemia, t(8;21)(q22;q22) RUNX1-RUNX1T1
9897/3: Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL
9898/3: Myeloid leukemia associated w/Down Syndrome
9910/3: Acute megakaryoblastic leukemia
9911/3: Acute myeloid leuk (megakaryobl) w/t(1;22)(p13;q13)
9920/3: Therapy-related (acute) myeloid neoplasm
9930/3: Myeloid sarcoma
9931/3: Acute panmyelosis with myelofibrosis
9940/3: Hairy cell leukemia
9945/3: Chronic myelomonocytic leukemia, NOS
9946/3: Juvenile myelomonocytic leukemia
9948/3: Aggressive NK-cell leukemia
9950/3: Polycythemia vera
9960/3: Chronic myeloproliferative disease, NOS (OBS 2010+) see 9975/3
9961/3: Primary myelofibrosis/myelosclerosis with myeloid metaplasia
9962/3: Essential thrombocytemia
9963/3: Chronic neutrophilic leukemia
9964/3: Chronic eosinophilic leukemia (hypereosinophilic syndrome), NOS
9965/3: Myeloid and lymphoid neoplasms w/PDGFRα rearrange
9966/3: Myeloid and lymphoid neoplasms w/PDGFRB rearrange
9967/3: Myeloid and lymphoid neoplasm w/FGFR1 abnormalities
9970/1: Lymphoproliferative disorder, borderline
9970/3: Lymphoproliferative disorder (disease), NOS (malig only prior to 2010)
9971/3: Polymorphic PTLD
9975/3: Myelodysp./myeloproliferative neoplasm unclass (malig only before 2010)
9980/3: Refractory anemia
9982/3: Refractory anemia with sideroblasts
9983/3: Refractory anemia with excess blasts
9984/3: Refractory anemia w. excess blasts in transformation
9985/3: Refractory cytopenia with multilineage dysplasia
9986/3: Myelodysplastic syndrome associated with isolated del(5q)
9987/3: Therapy related myelodysplastic syndrome, NOS (OBS 2010+) See 9920/3
9989/3: Myelodysplastic syndrome, unclassifiable or NOS
9991/3: Refractory neutropenia
9992/3: Refractory thrombocytopenia
**Summary Stage:** single variable based on SEER Summary Stage 77, 2000, Derived (combined based on dx year)  
   IS, L, R, D, unknown

**Laterality:**  
Not a paired site, Right (origin of primary), Left (origin of primary), Only one side—side unspecified, Bilateral-single primary, Paired site—midline tumor, Paired site—but no information

**Grade:**  
Well differentiated; Grade I  
Moderately differentiated; Grade II  
Poorly differentiated; Grade III  
Undifferentiated; anaplastic; Grade IV  
T-cell  
B-cell; pre-B; B-precursor  
Null cell; non T-non B  
NK cell; natural killer cell  
Unknown
ICCC: based on ICD-O-3 regardless of diagnosis date
I Leukemias, myeloproliferative & myelodysplastic diseases
   I(a) Lymphoid leukemias
   I(b) Acute myeloid leukemias
   I(c) Chronic myeloproliferative diseases
   I(d) Myelodysplastic syndrome and other myeloproliferative
   I(e) Unspecified and other specified leukemias
II Lymphomas and reticuloendothelial neoplasms
   II(a) Hodgkin lymphomas
   II(b) Non-Hodgkin lymphomas (except Burkitt lymphoma)
   II(c) Burkitt lymphoma
   II(d) Miscellaneous lymphoreticular neoplasms
   II(e) Unspecified lymphomas
III CNS and misc intracranial and intraspinal neoplasms
   III(a) Ependymomas and choroid plexus tumor
   III(b) Astrocytomas
   III(c) Intracranial and intraspinal embryonal tumors
   III(d) Other gliomas
   III(e) Other specified intracranial/intraspinal neoplasms
   III(f) Unspecified intracranial and intraspinal neoplasms
IV Neuroblastoma and other peripheral nervous cell tumors
   IV(a) Neuroblastoma and ganglioneuroblastoma
   IV(b) Other peripheral nervous cell tumors
V Retinoblastoma
VI Renal tumors
   VI(a) Nephroblastoma and other nonepithelial renal tumors
   VI(b) Renal carcinomas
   VI(c) Unspecified malignant renal tumors
VII Hepatic tumors
   VII(a) Hepatoblastoma
   VII(b) Hepatic carcinomas
   VII(c) Unspecified malignant hepatic tumors
VIII Malignant bone tumors
   VIII(a) Osteosarcomas
   VIII(b) Chondrosarcomas
VIII(c) Ewing tumor and related sarcomas of bone
VIII(d) Other specified malignant bone tumors
VIII(e) Unspecified malignant bone tumors
IX Soft tissue and other extraosseous sarcomas
  IX(a) Rhabdomyosarcomas
  IX(b) Fibrosarcomas, peripheral nerve & other fibrous
  IX(c) Kaposi sarcoma
  IX(d) Other specified soft tissue sarcomas
  IX(e) Unspecified soft tissue sarcomas
X Germ cell & trophoblastic tumors & neoplasms of gonads
  X(a) Intracranial & intraspinal germ cell tumors
  X(b) Extracranial & extragonadal germ cell tumors
  X(c) Malignant gonadal germ cell tumors
  X(d) Gonadal carcinomas
  X(e) Other and unspecified malignant gonadal tumors
XI Other malignant epithelial neoplasms and melanomas
  XI(a) Adrenocortical carcinomas
  XI(b) Thyroid carcinomas
  XI(c) Nasopharyngeal carcinomas
  XI(d) Malignant melanomas
  XI(e) Skin carcinomas
  XI(f) Other and unspecified carcinomas
XII Other and unspecified malignant neoplasms
  XII(a) Other specified malignant tumors
  XII(b) Other unspecified malignant tumors
Not classified by ICCC or in situ
Report Source: only 2 codes—other; DCO or autopsy only

CBTRUS Brain groupings based on site and histology: Updated by CBTRUS, See Appendix A

MP based on IARC Rules: check Y/N

MP based on SEER Rules: check Y/N

County-Level Urban/Rural Status: Based on Beale codes
  Metro, Non-Metro, unknown

County-level poverty: Based on ACS % living in poverty rolling 5 year-average (linked to date of diagnosis)
  <5%, 5-9.9%, 10-19.99%, 20%+, unknown

SES Composite (SEER): based on ACS data, county-level not tract because we do not currently have denominator (US only). Components include: Occupation, Unemployment, Poverty, Income, Education, Housing (price, ownership, crowding).
Appendix A. CBTRUS site/histology groups for malignant and non-malignant brain and CNS tumors. The variable is histologic group for malignant (Table 2b) and non-malignant (Table 2c) brain and CNS tumors (based on Table 1).

Table 1. Central Brain Tumor Registry of the United States (CBTRUS), Brain and Central Nervous System Tumor Site Groupings

<table>
<thead>
<tr>
<th>Site</th>
<th>ICD-O-3® Site Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebrum</td>
<td>C71.0</td>
</tr>
<tr>
<td>Frontal lobe of brain</td>
<td>C71.1</td>
</tr>
<tr>
<td>Temporal lobe of brain</td>
<td>C71.2</td>
</tr>
<tr>
<td>Parietal lobe of brain</td>
<td>C71.3</td>
</tr>
<tr>
<td>Occipital lobe of brain</td>
<td>C71.4</td>
</tr>
<tr>
<td>Ventricle</td>
<td>C71.5</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>C71.6</td>
</tr>
<tr>
<td>Brain stem</td>
<td>C71.7</td>
</tr>
<tr>
<td>Other brain</td>
<td>C71.8-C71.9</td>
</tr>
<tr>
<td>Overlapping lesion of brain</td>
<td>C71.8</td>
</tr>
<tr>
<td>Brain, NOS</td>
<td>C71.9</td>
</tr>
<tr>
<td>Spinal cord and cauda equina</td>
<td>C72.0-C72.1</td>
</tr>
<tr>
<td>Spinal cord</td>
<td>C72.0</td>
</tr>
<tr>
<td>Cauda equina</td>
<td>C72.1</td>
</tr>
<tr>
<td>Cranial nerves</td>
<td>C72.2-C72.3</td>
</tr>
<tr>
<td>Olfactory nerve</td>
<td>C72.2</td>
</tr>
<tr>
<td>Optic nerve</td>
<td>C72.3</td>
</tr>
<tr>
<td>Acoustic nerve</td>
<td>C72.4</td>
</tr>
<tr>
<td>Cranial nerve, NOS</td>
<td>C72.5</td>
</tr>
<tr>
<td>Other nervous system</td>
<td>C72.8-C72.9</td>
</tr>
<tr>
<td>Overlapping lesion of brain and central nervous system</td>
<td>C72.8</td>
</tr>
<tr>
<td>Nervous system, NOS</td>
<td>C72.9</td>
</tr>
<tr>
<td>Meninges (cerebral &amp; spinal)</td>
<td>C70.0-C70.1, C70.9</td>
</tr>
<tr>
<td>Cerebral meninges</td>
<td>C70.0</td>
</tr>
<tr>
<td>Spinal meninges</td>
<td>C70.1</td>
</tr>
<tr>
<td>Meninges, NOS</td>
<td>C70.9</td>
</tr>
<tr>
<td>Pituitary and cranial nerve duct</td>
<td>C75.1-C75.2</td>
</tr>
<tr>
<td>Pituitary gland</td>
<td>C75.1</td>
</tr>
<tr>
<td>Cranial nerve duct</td>
<td>C75.2</td>
</tr>
<tr>
<td>Pineal gland</td>
<td>C75.3</td>
</tr>
<tr>
<td>Salivary tumors of the nasal cavity*</td>
<td>C30.0</td>
</tr>
</tbody>
</table>

World Health Organization, Geneva, Switzerland.

ICD-O-3® histology codes 9521-9523 only.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.
<table>
<thead>
<tr>
<th>Histology</th>
<th>ICD-O-3 Histology Code</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tumors of Neuroepithelial Tissue</strong></td>
<td></td>
</tr>
<tr>
<td>Pilocytic astrocytoma*</td>
<td>9421/1</td>
</tr>
<tr>
<td>Diffuse astrocytoma*</td>
<td>9400/3, 9410/3, 9413/3, 9420/3</td>
</tr>
<tr>
<td>Anaplastic astrocytoma*</td>
<td>9401/3</td>
</tr>
<tr>
<td>Mixed glioma, malignant</td>
<td>9387/3, 9424/3</td>
</tr>
<tr>
<td>Glioblastoma*</td>
<td>9420/3, 9414/3, 9442/3</td>
</tr>
<tr>
<td>Anaplastic oligodendroglioma*</td>
<td>9450/3</td>
</tr>
<tr>
<td>Oligodendroglioma*</td>
<td>9451/3, 9460/3</td>
</tr>
<tr>
<td>Oligoastrocytic tumors*</td>
<td>9382/3</td>
</tr>
<tr>
<td>Ependymal tumors*</td>
<td>9391/3, 9392/3, 9393/3</td>
</tr>
<tr>
<td>Glioma, malignant, NOS*</td>
<td>9380/3, 9431/1, 9432/1 [Included with malignant tumors]</td>
</tr>
<tr>
<td>Chordoid glioma*</td>
<td>9390/3</td>
</tr>
<tr>
<td>Other astrocytic tumors*</td>
<td>9423/3, 9430/3</td>
</tr>
<tr>
<td>High-grade astrocytic tumors*</td>
<td>9423/3</td>
</tr>
<tr>
<td>Other tumors of neural-crest origin*</td>
<td>9362/3, 9395/3</td>
</tr>
<tr>
<td>Embryonal tumors</td>
<td>8963/3, 9364/3, 9470/3, 9471/3, 9472/3, 9473/3, 9474/3, 9480/3, 9490/3, 9500/3, 9501/3, 9502/3, 9508/3</td>
</tr>
<tr>
<td><strong>Tumors of Cranial and Spinal Nerves</strong></td>
<td></td>
</tr>
<tr>
<td>Nerve sheath tumors</td>
<td>9540/3, 9560/3, 9561/3, 9571/3</td>
</tr>
<tr>
<td><strong>Tumors of Meninges</strong></td>
<td></td>
</tr>
<tr>
<td>Meningioma</td>
<td>9330/3, 9353/3, 9539/3</td>
</tr>
<tr>
<td>Primary melanotic mesothelioma</td>
<td>8720/3, 8728/3, 8770/3, 8771/3</td>
</tr>
<tr>
<td>Other neoplasms related to the meninges</td>
<td>9212/3, 9213/3, 9340/3, 9343/3, 9370/3, 9371/3, 9372/3</td>
</tr>
<tr>
<td>Lymphomas and Hemopoietic Neoplasms</td>
<td></td>
</tr>
<tr>
<td>Germ Cell Tumors and Cysts</td>
<td>8020/3, 8440/3, 9060/3, 9061/3, 9064/3, 9065/3, 9070/3, 9071/3, 9072/3, 9080/3, 9081/3, 9082/3, 9083/3, 9084/3, 9085/3, 9100/3, 9101/3</td>
</tr>
<tr>
<td>Germ cell tumors, cysts and heterotopias</td>
<td>8020/3, 8440/3, 9060/3, 9061/3, 9064/3, 9065/3, 9070/3, 9071/3, 9072/3, 9080/3, 9081/3, 9082/3, 9083/3, 9084/3, 9085/3, 9100/3, 9101/3</td>
</tr>
<tr>
<td>Tumors of Sellar Region</td>
<td></td>
</tr>
<tr>
<td>Tumors of the pituitary</td>
<td>8110/3, 8112/3, 8120/3, 8121/3, 8122/3, 8123/3</td>
</tr>
<tr>
<td>Unclassified Tumors</td>
<td></td>
</tr>
<tr>
<td>Hemangioma</td>
<td>9120/3, 9130/3, 9133/3, 9140/3</td>
</tr>
<tr>
<td>Neoplasms, unspecified</td>
<td>8000/3, 8001/3, 8002/3, 8003/3, 8004/3, 8005/3, 8010/3, 8021/3</td>
</tr>
<tr>
<td>All other</td>
<td>8320/3, 8370/3, 8711/3, 8811/3, 8840/3, 8890/3, 8980/3, 9503/3, 9580/3</td>
</tr>
</tbody>
</table>

*Includes all the Histologies listed in the standard definition of reportable brain tumors from the Consensus Conference on Brain Tumor Definitions.

*See the CBTRUS website for additional information about the specific histology codes included in each group: http://www.cbtrus.org.

*All or some of this histology is included in the CBTRUS definition of gliomas, including ICD-O-3 Histology codes 9380-9388, 9391-9460.

Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.
<table>
<thead>
<tr>
<th>Table 2c. Central Brain Tumor Registry of the United States (CBTRUS), Brain and Central Nervous System Tumor Non-Malignant Histologiesa</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Histology</strong></td>
</tr>
<tr>
<td><strong>Tumors of Neuroepithelial Tissue</strong></td>
</tr>
<tr>
<td>Unique astrocytoma variants*</td>
</tr>
<tr>
<td>Epithelial tumors*</td>
</tr>
<tr>
<td>Choroid plexus</td>
</tr>
<tr>
<td>Other neuroepithelial tumors</td>
</tr>
<tr>
<td>Neuronal and mixed neuronal-glial tumors*</td>
</tr>
<tr>
<td>Tumors of the pineal region</td>
</tr>
<tr>
<td>Embryonal tumors</td>
</tr>
<tr>
<td><strong>Tumors of Cranial and Spinal Nerves</strong></td>
</tr>
<tr>
<td>Nerve sheath tumors</td>
</tr>
<tr>
<td>Other tumors of cranial and spinal nerves</td>
</tr>
<tr>
<td><strong>Tumors of Meninges</strong></td>
</tr>
<tr>
<td>Meningioma</td>
</tr>
<tr>
<td>Mesenchymal tumors</td>
</tr>
<tr>
<td>Primary melanocytic lesions</td>
</tr>
<tr>
<td>Other neoplasms related to the meninges</td>
</tr>
<tr>
<td><strong>Lymphomas and Hematopoietic Neoplasms</strong></td>
</tr>
<tr>
<td>Other hematopoietic neoplasms</td>
</tr>
<tr>
<td>Germ cell tumors and cysts</td>
</tr>
<tr>
<td><strong>Tumors of Sellar Region</strong></td>
</tr>
<tr>
<td>Tumors of the pituitary gland</td>
</tr>
<tr>
<td>Craniopharyngioma</td>
</tr>
<tr>
<td>Unclassified Tumors</td>
</tr>
<tr>
<td>Hemangioma</td>
</tr>
<tr>
<td>Neoplasm, unspecified</td>
</tr>
<tr>
<td>All other</td>
</tr>
</tbody>
</table>

*aIncludes all the histologies listed in the standard definition of reportable brain tumors from the Consensus Conference on Brain Tumor Definition.

*See the CBTRUS website for additional information about the specific histology codes included in each group: http://www.cbtrus.org.

*All or some of this histology is included in the CBTRUS definition of gliomas, including ICD-O-3 Histology codes 9386–9384, 9391–9460.

Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.